Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pidilizumab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Orticumab, an antibody targeting OxLDL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Blosozumab, an antibody targeting Sclerostin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ontuxizumab, an antibody targeting CD248.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tarextumab, an antibody targeting NOTCH2 and NOTCH3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bimagrumab, an antibody targeting ACVR2B.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Codrituzumab, an antibody targeting GPC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abituzumab, an antibody targeting ITGAV.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Coltuximab, an antibody targeting CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lilotomab, an antibody targeting CD37.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Varlilumab, an antibody targeting TNFRSF7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tesidolumab, an antibody targeting C5.